# CiLostAzol for pReventIon of Recurrent sTroke in Africa

> **NCT06919835** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Northern California Institute of Research and Education** · enrollment: 1100 (estimated)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** Cilostazol 100 mg

## Key facts

- **NCT ID:** NCT06919835
- **Lead sponsor:** Northern California Institute of Research and Education
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2028-12-31
- **Target enrollment:** 1100 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06919835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06919835, "CiLostAzol for pReventIon of Recurrent sTroke in Africa". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06919835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*